Search

Quick takes: FDA panel backs RSV preventive, Tpoxx trial enrollment, more polio cases

The FDA antimicrobial drugs advisory committee unanimously recommended nirsevimab for preventing respiratory syncytial virus in infants during their first RSV season.

Lisa Schnirring

Study shows detectable mpox DNA in skin lesions for more than 3 weeks

Among 16 men who have sex with men infected with mpox, viral DNA remained detectable for 17 to 31 days after symptom onset.

Stephanie Soucheray

AI can accurately diagnose mpox using photos of rash, researchers say

Scientists used artificial intelligence to diagnose mpox using photos of skin lesions with an accuracy up to 99.5%.

Mary Van Beusekom

Quick takes: Peruvian dengue surge, polio in Africa, mpox cases in Colorado

With record dengue cases already this year, Peru is bracing for more heavy rains in the months ahead from the El Nino weather pattern.

Lisa Schnirring

Spanish study shows efficacy of Jynneos mpox vaccine is 89%

For those who got sick, vaccinated patients had fewer symptoms and none required hospitalization.

Stephanie Soucheray

Global mpox cases rise slightly, with more deaths reported

The WHO says cases have risen 1%, and, of 11 countries reporting increases, the largest was in Mexico.

Lisa Schnirring

One dose of Jynneos mpox vaccine 86% effective, study suggests

The estimated vaccine effectiveness of one subcutaneous dose of the Jynneos mpox vaccine among men in Israel is 86%.

Mary Van Beusekom

WHO says it will maintain global health emergency for mpox

Experts conclude that sustained incidence of illness in a few nations, along with underreported detection of cases, was enough to maintain emergency status.

Chris Dall

Quick takes: Universal flu vaccine trial launch, MERS vaccine trial in seniors, funds for mRNA mpox vaccine

Groups announced new clinical trials and more support for universal flu, MERS, and mpox vaccines.

Lisa Schnirring

Global mpox spread continues at low levels, with hot spots in parts of Asia

China is one of the current hot spots in Asia and reported 501 cases in August.

Lisa Schnirring

Smallpox vaccine given years before 72% to 75% effective against mpox, data reveal

Of the 29% of veterans who tested positive for orthopoxvirus, 3% had been vaccinated with Dryvax, and 7% had received ACAM2000.

Mary Van Beusekom

Study: Immunity from infection a major driver in Netherlands mpox decline

Cases started declining before the vaccine campaign launched.

Lisa Schnirring

8.5 days elapse between successive mpox cases, study estimates

The average time for symptom onset between successive cases (serial interval) is 8.5 days, and the time from infection to symptom onset (incubation period) is 5.6 days, new data show.

Mary Van Beusekom

1-dose Jynneos vaccine effectiveness against symptomatic mpox estimated at 78%

Estimated 1-dose protection against symptomatic mpox was 78% after at least 14 days, ranging from 71% to 85% in sensitivity analyses.

Mary Van Beusekom

Study finds most mpox videos on TikTok are incomplete, inaccurate

Of the 85 videos analyzed, only 33% covered all content items that were highlighted in clinical practice guidelines.

Chris Dall

WHO reports mpox decline in most regions, but more deaths

The Americas reported the vast majority of new cases over the past 3 weeks—408 of 442.

Lisa Schnirring

Quick takes: Listeria recalls expand, CDC mpox vaccine reminder, Oregon plague case

As small clusters continue, the CDC notes that only 1 in 4 eligible people have received both mpox vaccine doses.

Lisa Schnirring

Clinical mpox diagnosis tracks closely with lab confirmation

Sensitivity was 99% for all patients and 100% in the people affected by HIV.

Lisa Schnirring

ECDC weighs in on wider risk from DRC mpox outbreak clade

Prior infection from a clade 2 infection, as well as vaccination, could decrease the impact on at-risk groups.

Lisa Schnirring

Roughly 1% of gay, bisexual men in Portugal had mpox during 2022 outbreak

Of the 399 cases with information on probable transmission routes, 95.2% identified sexual contact, 3.3% cited nonsexual contact, and 0.5% reported healthcare-associated spread.

Mary Van Beusekom

News Scan for Nov 21, 2017

Animal Zika studies shed light on transmission, paralysis complications

Experiments in guinea pigs to explore possible routes of Zika transmission found that infected animals can pass the virus to healthy cagemates, perhaps through tears or saliva, researchers from China reported today in Nature Communications.

News Scan for Nov 29, 2017

Another case of MERS reported in Bisha

The Saudi Arabian Ministry of Health (MOH) today reported a new case of MERS-CoV in Bisha, the third within the last week.

A 67-year-old Saudi woman is in stable condition after presenting with symptoms of MERS-CoV (Middle East respiratory syndrome coronavirus) infection. Her source of infection is listed as "primary," meaning it's unlikely she contracted the virus from another person.

News Scan for Dec 19, 2017

Nigeria monkeypox outbreak grows to 61 confirmed cases

According to an updated situation report from the Nigeria Centre for Disease Control (NCDC), there are now 61 monkeypox cases in that country, 5 more than last month. This is Africa's largest-ever monkeypox outbreak.

News Scan for Dec 22, 2017

WHO advisors to conduct full review of Dengvaxia data

Today the World Health Organization (WHO) updated its Q and A document that covers developments surrounding Dengvaxia, Sanofi's dengue vaccine. It says its Strategic Advisory Groups of Experts (SAGE) will undertake a full rigorous view of new data to update its position paper on the vaccine, which won't likely be available until after April 2018.

News Scan for Jan 03, 2018

Two new MERS cases confirmed in Saudi Arabia

The Saudi Arabian Ministry of Health (MOH) recorded two new cases of MERS-CoV in the past several days.

On Dec 30, a 55-year-old expatriate man from Khamis Mushait was diagnosed as having MERS-CoV (Middle East respiratory syndrome coronavirus) after presenting with symptoms. He is in critical condition. The man's source of infection is listed as "primary," meaning it's unlikely he contracted the virus from another person.

Our underwriters